New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
08:06 EDTARNAArena Pharmaceuticals initiates Phase 1b clinical trial of APD334
Arena Pharmaceuticals announced the initiation of dosing in an investigational Phase 1b clinical trial of APD334, a novel, oral drug candidate that targets the sphingosine 1-phosphate subtype 1 receptor, to evaluate the compound for the treatment of a number of autoimmune diseases. This randomized, double-blind and placebo-controlled Phase 1b trial will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD334 in up to 96 healthy adult volunteers.
News For ARNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 11, 2015
19:15 EDTARNAOn The Fly: After Hours Movers
Subscribe for More Information
16:41 EDTARNAArena Pharmaceuticals reports Q1 EPS (10c), consensus (14c)
Subscribe for More Information
16:22 EDTARNAArena Pharmaceuticals enters collaboration with Roivant Sciences
Arena Pharmaceuticals announced that its subsidiary, Arena Pharmaceuticals GmbH, and Roivant Sciences Ltd., have entered into a Development, Marketing and Supply Agreement for nelotanserin, Arena's internally discovered inverse agonist of the 5-HT2A receptor. The agreement grants Roivant exclusive worldwide rights to develop and commercialize nelotanserin. Nelotanserin has been studied to date in multiple clinical trials involving over 900 subjects. Roivant intends to initiate additional Phase 2 clinical trials for the treatment of behavioral and neuropsychiatric disturbances, including psychoses, in patients with dementia and other neurological diseases. In addition, Roivant may pursue the development of nelotanserin for other neuropsychiatric disorders. Roivant will be responsible for funding the development and commercialization of nelotanserin. Under the agreement, Arena will manufacture clinical supply and commercial product to sell to Roivant. Arena will receive a $4.0M upfront payment and is eligible to receive $41.5M in regulatory and development milestone payments. Arena is also eligible to receive 15% of net sales of nelotanserin in exchange for the manufacture and supply of finished commercial drug product, and up to a total of $60.0M in one-time purchase price adjustment payments tied to certain commercial sales milestones.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use